Fitness comparison of thymidine analog resistance pathways in human immunodeficiency virus type 1

被引:53
作者
Hu, Zixin
Giguel, Francoise
Hatano, Hiroyu
Reid, Patrick
Lu, Jing
Kuritzkes, Daniel R.
机构
[1] Brigham & Womens Hosp, Sect Retroviral Therapeut, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Div AIDS, Boston, MA USA
关键词
D O I
10.1128/JVI.02747-05
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Resistance to zidovudine (ZDV) results from thymidine analog resistance mutations (TAMS) at human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) codons 41, 67, 70, 210, 215, and 219. Two mutations are possible at codon 215:Y or F. Whereas T215Y occurs alone or with M41L and L210W (TAM-1 pattern), T215F rarely occurs with these mutations or by itself; it is found instead with D67N, K70R, and K219Q (TAM-2 pattern). The L210W mutation most often occurs with M41L and T215Y and rarely occurs with the T215F or TAM-2 mutation. To explain these associations, TAMS were introduced into HIV-1(Hxb2) by site-directed mutagenesis and expressed in recombinant viruses. Viral replication kinetics, relative fitness, and infectivity were tested in the absence or presence of ZDV. Viruses carrying the 215Y mutation showed faster replication kinetics and greater relative fitness than did T215F mutants in the absence or presence of ZDV. In addition, T215Y mutants showed greater infectivity than did wild-type HIV-1 over a range of ZDV concentrations, but T215F mutants had only a modest advantage over the wild-type virus. Whereas introduction of L210W improved the relative fitness of an M41L/T215Y mutant in the presence of ZDV, introduction of this mutation into a D67N/K70R/K219Q background resulted in decreased relative fitness in the presence or absence of drug. By contrast, introduction of T215F into the D67N/K70R/K219Q background increased viral fitness in the presence of ZDV. These results help explain why T215Y but not T215F usually emerges as the first major TAM, as well as the clustering of L210W with TAM-1 mutations and T215F with TAM-2 mutations.
引用
收藏
页码:7020 / 7027
页数:8
相关论文
共 37 条
  • [1] Phenotypic mechanism of HIV-1 resistance to 3′-azido-3′-deoxythymidine (AZT):: Increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase
    Arion, D
    Kaushik, N
    McCormick, S
    Borkow, G
    Parniak, MA
    [J]. BIOCHEMISTRY, 1998, 37 (45) : 15908 - 15917
  • [2] ORDERED APPEARANCE OF ZIDOVUDINE RESISTANCE MUTATIONS DURING TREATMENT OF 18 HUMAN IMMUNODEFICIENCY VIRUS-POSITIVE SUBJECTS
    BOUCHER, CAB
    OSULLIVAN, E
    MULDER, JW
    RAMAUTARSING, C
    KELLAM, P
    DARBY, G
    LANGE, JMA
    GOUDSMIT, J
    LARDER, BA
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1992, 165 (01) : 105 - 110
  • [3] Selective excision of AZTMP by drug-resistant human immunodeficiency virus reverse transcriptase
    Boyer, PL
    Sarafianos, SG
    Arnold, E
    Hughes, SH
    [J]. JOURNAL OF VIROLOGY, 2001, 75 (10) : 4832 - 4842
  • [4] Crystal structures of zidovudine- or lamivudine-resistant human immunodeficiency virus type 1 reverse transcriptases containing mutations at codons 41, 184, and 215
    Chamberlain, PP
    Ren, J
    Nichols, CE
    Douglas, L
    Lennerstrand, J
    Larder, BA
    Stuart, DI
    Stammers, DK
    [J]. JOURNAL OF VIROLOGY, 2002, 76 (19) : 10015 - 10019
  • [5] REDUCTION OF MATERNAL-INFANT TRANSMISSION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 WITH ZIDOVUDINE TREATMENT
    CONNOR, EM
    SPERLING, RS
    GELBER, R
    KISELEV, P
    SCOTT, G
    OSULLIVAN, MJ
    VANDYKE, R
    BEY, M
    SHEARER, W
    JACOBSON, RL
    JIMENEZ, E
    ONEILL, E
    BAZIN, B
    DELFRAISSY, JF
    CULNANE, M
    COOMBS, R
    ELKINS, M
    MOYE, J
    STRATTON, P
    BALSLEY, J
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (18) : 1173 - 1180
  • [6] Mutations in the pol gene of human immunodeficiency virus type 1 in infected patients receiving didanosine and hydroxyurea combination therapy
    DeAntoni, A
    Foli, A
    Lisziewicz, J
    Lori, F
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1997, 176 (04) : 899 - 903
  • [7] Host-parasite dynamics and outgrowth of virus containing a single K70R amino acid change in reverse transcriptase are responsible for the loss of human immunodeficiency virus type 1 RNA load suppression by zidovudine
    deJong, MD
    Veenstra, J
    Stilianakis, NI
    Schuurman, R
    Lange, JMA
    deBoer, RJ
    Boucher, CAB
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (11) : 5501 - 5506
  • [8] A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
    Hammer, SM
    Squires, KE
    Hughes, MD
    Grimes, JM
    Demeter, LM
    Currier, JS
    Eron, JJ
    Feinberg, JE
    Balfour, HH
    Dayton, LR
    Chodakewitz, JA
    Fischl, MA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (11) : 725 - 733
  • [9] A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter
    Hammer, SM
    Katzenstein, DA
    Hughes, MD
    Gundacker, H
    Schooley, RT
    Haubrich, RH
    Henry, WK
    Lederman, MM
    Phair, JP
    Niu, M
    Hirsch, MS
    Merigan, TC
    Blaschke, TF
    Simpson, D
    McLaren, C
    Rooney, J
    Salgo, M
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (15) : 1081 - 1090
  • [10] Patterns of resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine, and nevirapine
    Hanna, GJ
    Johnson, VA
    Kuritzkes, DR
    Richman, DD
    Brown, AJL
    Savara, AV
    Hazelwood, JD
    D'Aquila, RT
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2000, 181 (03) : 904 - 911